pubmed-article:18992284 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0379710 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0017636 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0001807 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0021701 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0851285 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C1741686 | lld:lifeskim |
pubmed-article:18992284 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
pubmed-article:18992284 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:18992284 | pubmed:dateCreated | 2009-1-26 | lld:pubmed |
pubmed-article:18992284 | pubmed:abstractText | Caveolin-1 plays a checkpoint function in the regulation of processes often altered in cancer. Although increased expression of caveolin-1 seems to be the norm in the glioma family of malignancies, populations of caveolin-1 positive and negative cells coexist among glioblastoma specimens. As no data are available to date on the contribution of such cells to the phenotype of glioblastoma, we manipulated caveolin-1 in the glioblastoma cell line U87MG. We showed that caveolin-1 plays a critical role in the aggressiveness of glioblastoma. We identified integrins as the main set of genes affected by caveolin-1. We reported here that the phenotypic changes observed after caveolin-1 modulation were mediated by alpha(5)beta(1) integrins. As a consequence of the regulation of alpha(5)beta(1) levels by caveolin-1, the sensitivity of cells to the specific alpha(5)beta(1) integrin antagonist, SJ749, was affected. Mediator of caveolin-1 effects, alpha(5)beta(1) integrin, is also a marker for glioma aggressiveness and an efficient target for the treatment of glioma especially the ones exerting the highest aggressive phenotype. | lld:pubmed |
pubmed-article:18992284 | pubmed:language | eng | lld:pubmed |
pubmed-article:18992284 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18992284 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18992284 | pubmed:month | Feb | lld:pubmed |
pubmed-article:18992284 | pubmed:issn | 0006-3002 | lld:pubmed |
pubmed-article:18992284 | pubmed:author | pubmed-author:DontenwillMon... | lld:pubmed |
pubmed-article:18992284 | pubmed:author | pubmed-author:TakedaKenK | lld:pubmed |
pubmed-article:18992284 | pubmed:author | pubmed-author:MartinSophieS | lld:pubmed |
pubmed-article:18992284 | pubmed:author | pubmed-author:TerrandJérôme... | lld:pubmed |
pubmed-article:18992284 | pubmed:author | pubmed-author:MaglottAnneA | lld:pubmed |
pubmed-article:18992284 | pubmed:author | pubmed-author:CossetErika... | lld:pubmed |
pubmed-article:18992284 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:18992284 | pubmed:volume | 1793 | lld:pubmed |
pubmed-article:18992284 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18992284 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18992284 | pubmed:pagination | 354-67 | lld:pubmed |
pubmed-article:18992284 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:meshHeading | pubmed-meshheading:18992284... | lld:pubmed |
pubmed-article:18992284 | pubmed:year | 2009 | lld:pubmed |
pubmed-article:18992284 | pubmed:articleTitle | Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. | lld:pubmed |
pubmed-article:18992284 | pubmed:affiliation | Université Strasbourg 1 Institut Gilbert Laustriat, CNRS UMR 7175, Illkirch, France. Sophie.Martin@pharma.u-strasbg.fr | lld:pubmed |
pubmed-article:18992284 | pubmed:publicationType | Journal Article | lld:pubmed |
entrez-gene:857 | entrezgene:pubmed | pubmed-article:18992284 | lld:entrezgene |
entrez-gene:3678 | entrezgene:pubmed | pubmed-article:18992284 | lld:entrezgene |
entrez-gene:3688 | entrezgene:pubmed | pubmed-article:18992284 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18992284 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18992284 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18992284 | lld:entrezgene |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18992284 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18992284 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18992284 | lld:pubmed |